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Mechanism of blood pressure reduction by teprotide (SQ 20881)
in rats. The mechanism by which the angiotensin converting
enzyme inhibitor, teprotide (SQ 20881), lowers blood pressure was
assessed in anesthetized normotensive and spontaneously hyper-
tensive (SHR) rats. Teprotide always was administered at a maxi-
mally effective dose of 1 mg/kg. In six normal Wistar rats, tepro-
tide lowered blood pressure only after sodium depletion, an effect
which was abolished by bilateral nephrectomy. Saralasin infusion
(5 p.g/kg/min) into salt-depleted normal rats induced a blood pres-
sure effect similar to that of teprotide. When administered in
addition to saralasin infusion, teprotide did not reduce blood pres-
sure further in nonnal rats or in SHR. When blood pressure of
normal rats was raised by angiotensin II infusion (200 ng/kg/min),
teprotide did not affect the induced blood pressure increase. In
contrast, the pressure rise induced by angiotensin I infusion (230
ng/kg/min) was reversed by saralasin, but again concomitant ad-
ministration of teprotide did not induce further blood pressure
reduction. Thus, under the particular conditions of the present
study, teprotide did not appear to exert its hypotensive effect by
any mechanism other than inhibition of the renin-angiotensin sys-
tem. Furthermore, given at a maximally effective dose to the rat, it
produced no greater vasodepressor effect than did saralasin.
Mécanisme de Ia baisse de Ia pressioa artérielle obtenue chez le
rat par le téprotide (SQ 20881). Le mécanisme par lequel
l'inhibiteur de I'enzyme de conversion de l'angiotensine, le tépro-
tide (SQ 20881), abaisse la pression artérielle a été evalué chez des
rats anesthésiés, normaux ou atteints spontanément
d'hypertension artérielle (SHR). Le teprotide a toujours été ad-
ministré a une dose maximale efficace (1 mg/kg). Chez six rats
Wistar normaux, le teprotide n'abaisse la pression arterielle
qu'après depletion en sodium, cet effet est aboli par la nephrecto-
mie bilaterale. La perfusion de saralasine (5 ,tsg/kg/min) a des rats
normaux depletes en sd determine, sur Ia pression arterielle, un
effet semblable a celui du téprotide. Quand le téprotide est admin-
istré en méme temps que la perfusion de saralasine, il n'est pas
observe d'effet supplementaire sur la pression artérielle chez les
rats normaux ou les SHR. Quand Ia pression artérielle de rats
normaux est augmentee par une perfusion d'angiotensine 11(200
ng/kg/min), le teprotide n'affecte pas cette augmentation. Au con-
traire, l'augmentation de pression determinee par la perfusion
d'angiotensine 1(230 ng/kg/min) est abolie par la saralasine mais, là
encore, l'administration simultanee de teprotide ne determine pas
de supplement d'abaissement de Ia pression arterielle. Ainsi, dans
la limite des conditions de ce travail, le teprotide ne parait pas
exercer ses effets hypotensifs par un mecanisme different de
l'inhibition du systeme renine angiotensine. De surcroit, quand il
est administre a dose maximale au rat, il ne produit pas d'effet
vasodepresseur plus important que celui de Ia saralasine.
In recent years, the availability of specific antago-
nists has made it possible to study the actual role of
the renin-angiotensin system in normal and patholog-
ical states. Saralasin (P113) is a competitive antago-
nist of angiotensin II [1, 2]. Another polypeptide,
teprotide (SQ 20881), inhibits the enzyme that con-
verts angiotensin I to angiotensin II and simultane-
ously degrades circulating bradykinin [3, 4].
It has been suggested that these two inhibitors may
not be equally effective in blocking the renin-angio-
tensin system [5—7]. Under certain circumstances,
saralasin may actually exhibit an agonistic action,
i.e., angiotensin-like action [8, 9]. Conversely,
teprotide may owe a part of its vasodepressor effect
to inhibition of kininase II which could lead to brady-
kinin accumulation. This is of particular interest in
view of the close correlation that has been found
between plasma bradykinin, renin activity, and
angiotensin II with changes in sodium balance [10].
The purpose of the present studies was 1) to inves-
tigate whether teprotide's blood pressure effect is
due exclusively to its blocking effect on angiotensin
conversion and 2) to compare its effectiveness at
maximal doses to that of saralasin. The results sug-
gest that in the rat teprotide lowers blood pressure
solely by blocking the pressor effect of the renin-
angiotensin system. Moreover, under our experi-
mental conditions, it had no greater hypotensive ef-
fect than saralasin had.
Methods
Animals and procedures. Female albino rats of the
Wistar strain and spontaneously hypertensive rats
(SHR) were used. At the time of the experiments,
Received for publication June 27, 1977;
and in revised form October 20, 1977.
289
0085-2538/78/0013-0289 $01.60
© 1978, by the International Society of Nephrology.
290 Jaeger et al
both types of animals weighed 170 to 200 g and were
12 to 14 weeks old. All had free access to food and
tap water and were housed in a temperature-con-
trolled room (22 to 24° C). Normal diet consisted of
commercial rat pellets containing 90 j.tEq of sodium
and 240 pFq of potassium per gram. Sodium deple-
tion was accomplished by a single i.p. administration
of 10 mg/kg of body wt of furosemide, followed by
one week of a wheat diet containing 10 EqIg of
sodium. Twelve rats were bilaterally ne-
phrectomized through a thoracolumbar incision un-
der brief ether anesthesia 24 hr prior to experiment.
Food and water were withheld following nephrec-
tomy. The skin was closed by collodion.
On the day of experiment, all rats were anesthe-
tized with sodium pentobarbital (50 mg/kg of body
wt, i.p.). In the binephrectomized animals, the dose
administered was 42.5 mg/kg. The rats were then
placed in the recumbent position on an operating
table. Polyethylene catheters (PE =10) were inserted
in the right and left jugular veins for infusion or
injection of drugs. The cannulas were sized to con-
tain exactly 10 l of 5% dextrose. The left carotid
artery was cannulated with a tapered polyethylene
tube containing 0.5% heparin in 0.9% sodium chlo-
ride. Arterial pressure was transmitted through tub-
ing containing 0.9% sodium chloride, which was con
nected to a calibrated mercury colunm. Oscillations
in mean pressure were recorded throughout the
experiment by an ink stylus on paper, attached to a
Fleisch kymograph moving at a speed of 2 mmlmin.
In all cases, a tracheostomy was performed to facili-
tate respiration and removal of secretions. No tube
was left in the trachea, but the cephalic end was
ligated by a silk suture. Temperature was maintained
constant with a 60-watt worklamp positioned over
the rat and monitored by means of a rectal thermom-
eter. Injections were given i.v. as a bolus from a
microsyringe; infusions were delivered i.v. by means
of a Sage pump (model 355).
Experiments. Six types of experiments were com-
pleted on a total of 56 animals. The experimental
groups, the number of rats in each, and treatments
administered to the groups are summarized in
Table 1.
No experiment was begun until blood pressure had
been stable for at least 15 to 20 mm. Injections of
angiotensin II of 6.25, 12.5 and 25 ng were then given
i.v. to check the dose-related responsiveness of the
blood pressure. Doses of angiotensin I of 16 and 32
ng were injected in the same manner. After an appro-
priate interval, the respective treatment, shown in
Table 1, was administered. Teprotide (SQ 20881; the
Squibb Institute for Medical Research, Princeton,
N.J.) was always injected in a dose of 1 mg/kg of
body wt i.v. Saralasin (sar1-ala8-angiotensin II, P113;
Eaton Laboratories, Norwich, N.Y.) was infused at
a rate of 5 j.g/kgImin except in group VI where it was
given at a rate of 10 tg/kg/min. In groups V and VI,
angiotensin I and II were infused at rates sufficient to
raise mean arterial pressure by 15 to 20 mm Hg.
After the administration of teprotide or saralasin, the
injections of angiotensin I and II were repeated at the
same doses to check the percent blockade of each
agonist. In the absence of an angiotensin pressor
effect, the continued responsiveness of blood pres-
sure was then confirmed by the administration of
either 200 or 400 ng of norepinephrine.
Table 1. Experimental groups and treatments administered to each groupa
No. of
Rats Diet rats Treatment
Group I
A Normal Normal salt 6 SQ injection
B Normal Low salt 6 SQ injection
Group II
A Binephrectomized Normal salt 6 SQ injection
B Binephrectomized Low salt 6 SQ injection
Group III
A Normal Normal salt 6 P113 infusion + SQ injection
B Normal Low salt 6 P113 infusion + SQ injection
Group IV
A SHR Normal salt 3 P113 infusion + SQ injection
B SHR Low salt 3 P113 infusion + SQ injection
Group V
A Normal Normal salt 3 All infusion + SQ injection
B Normal Low salt 3 All infusion + SQ injection
Group VI
A Normal Normal salt 3 Al infusion + P113 infusion + SQ injection
B Normal Low salt 5 Al infusion + P113 infusion + SQ injection
a Abbreviations used are: SHR, spontaneously hypertensive rats; SQ, teprotide; P113, saralasin; Al, angiotensin I; All, angiotensin II.
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Drugs and solutions. Saralasin was provided at a
concentration of 5 mg/mi. The converting enzyme
inhibitor teprotide was diluted in 5% dextrose to a
concentration of 20 g/sl, which was then divided
into 5O-pi aliquots. Starting from a concentration of
650 sg/ml, which was checked by radioimmunoas-
say, angiotensin I was diluted in 5% dextrose to yield
a concentration of 3.25 ng/tl. Angiotensin II (Hyper-
tensin®, Ciba) was diluted in 5% dextrose to yield a
solution of 5 ng/4td. Norepinephrine was prepared
from a commercial 0.1% solution and was diluted
with 5% dextrose to 200 ng/Ll. The diluted aliquots
of angiotensin I and teprotide were kept frozen at
— 20° C and were thawed just before use.
Heparin, as heparin-lithium salt was diluted in
0.9% sodium chloride to a concentration of 0.5 g/100
ml. Sodium pentobarbital (Nembutal®), 50 mglml,
and furosemide (Lasix®), 10 mg/mi, were obtained as
commercial preparations.
Calculations. Results are expressed as means
SEM. Statistical analyses were performed using the
Student's t test for paired and unpaired data [11].
(For some groups, the number of animals was too
small to compute a t value.) In all cases in which it
was computed, P <0.05 was considered significant.
Inhibition of the maximal bolus dose (32 ng) of
angiotensin I was calculated following administration
of either one of the inhibitors. Complete abolition of
a pressor response was taken as 100% inhibition; in
the case of partial inhibition, the reduction of the
pressor response was expressed in percent of the
total control response determined before the admin-
istration of the antagonist.
Results
Teprotide in normal rats (group I). The effect of
teprotide alone was assessed in six rats on a normal
salt intake. Mean blood pressure decreased from 116
4.0 to 96 4.6 mm Hg (P <0.005); however, it
returned to baseline pressure within 6 to 10 mm (Fig.
1, upper left panel).
In six salt-depleted rats, the same treatment pro-
duced a similar immediate fall in blood pressure from
113 5.9 to 93 6.9mm Hg (P <0.005). In contrast
to the normal salt group, blood pressure did not
return to baseline but remained 11 1.9 mm Hg
below control level for at least one hour (Fig. 1,
upper right panel). This sustained decrease remained
statistically significant (P < 0.01).
A typical experiment in a salt-depleted rat is
shown in Figure 2. Blood pressure responses to in-
jections of several doses of angiotensin I and II were
monitored at the beginning of the experiment. Tepro-







Fig. 2. Representative experiment of the effect on mean blood
pressure of 1 mg/kg of teprotide (SQ) in a salt-depleted normal rat.
Injections of angiotensin 11(12.5 and 25 ng) and of angiotensin 1(16
and 32 ng) were given before and after injection of teprotide; in this
case, the converting enzyme antagonist reduced the pressor re-
sponse to angiotensin 1(32 ng) by 78%.
abrupt fall in pressure, followed by a lesser but
sustained decrease. After stabilization of blood pres-
sure, the identical doses of angiotensin I and II were
again administered. The rises in mean blood pressure
produced by equal doses of angiotensin II after the
blockade were slightly higher at + 27 2 mm Hg
than those of + 24 2 mm Hg (N = 11) observed
prior to blockade (P < 0.01). In contrast, the re-
sponses to angiotensin I were markedly inhibited
(see below).
Teprotide in bilaterally nephrectomized rats
(group II). Six rats on a regular diet and binephrec-
tomized 24 hr before the experiment exhibited an




















Fig. 1. Comparison of the effect on mean blood pressure of 1 mg/
kg of teprotide (SQ) in groups of anesthetized normal and bilater-
ally nephrectomized rats on normal and low-salt diets. Points
represent the mean, and vertical bars represent SEM of six rats in
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not significantly different from the mean pressure of
the normal rats of group I. Teprotide produced nei-
ther an immediate nor a delayed change in blood
pressure (Fig. 1, lower left panel).
In six salt-depleted binephrectomized rats, starting
blood pressure of 96 3.6 was significantly lower (P
< 0.05) than in the previously described groups.
Again, teprotide had no effect on blood pressure
(Fig. 1, lower right panel).
Teprotide together with saralasin infusion in nor-
mal rats (group III). In these experiments, saralasin
(5 g/kg/min) was infused into six normal rats on
normal diet. Saralasin produced an initial abrupt 7.8
4.0 mm Hg rise in blood pressure from a basal
value of 114 5.6 mm Hg (Fig. 3, upper left panel).
Blood pressure then fell quickly to 18 4.9 mm Hg
below baseline (P < 0.02), but returned within 15
mm to 114 5.6 mm Hg despite continuation of the
saralasin infusion. In every rat, additional adminis-
tration of teprotide was without any effect on blood
pressure.
Six salt-depleted normal rats (Fig. 3, upper right
panel) had a baseline pressure of 110 7.0 mm Hg,
which was not significantly different from the pre-
vious group. Saralasin produced the same initial
sharp rise in blood pressure of 4.6 1.2 mm Hg,
followed by a blood pressure reduction to 91 7.0
mm Hg (P < 0.001). In this case, however, mean
pressure did not return to baseline values with con-
tinued infusion, but remained at the same level of 90
8.1 mm Hg. As in the case of the rats on normal
diet, teprotide produced no detectable effect on
blood pressure when given in addition to saralasin.
Teprotide together with saralasin infusion in spon-
taneously hypertensive rats (group IV). Control
blood pressure of three spontaneously hypertensive
rats (SHR) on normal diet averaged 142 4.6 mm
Hg (Fig. 3, lower left panel). Immediately following
initiation of saralasin infusion, blood pressure rose
by 11.6 3.8 mm Hg and then fell to 124 9.2 mm
Hg. These blood pressure changes, however, were of
short duration, as in the normal rats, since blood
pressure returned within 10 mm to 150 5.8 mm Hg,
slightly above baseline values. Additional teprotide
produced no discernible change in blood pressure in
any of the animals.
Three salt-depleted spontaneously hypertensive
rats showed a more pronounced pattern than that
observed in salt-depleted normal rats. Mean pressure
rose by 5 1.5 from 158 3.7 mm Hg to fall
immediately afterwards to 106 4.6 mm Hg (P <
0.05). As in the salt-depleted normal rats, this blood
pressure reduction persisted during saralasin infu-
sion. Again, adding teprotide had no further effect in
any animal (Fig. 3, lower right panel).
All six spontaneously hypertensive rats, taken
together, exhibited a mean blood pressure decrease
with saralasin infusion from 150 4 to 129 10 mm
Hg. Following the addition of teprotide, their blood
pressure still averaged 128 10 mm Hg.
Teprotide together with angiotensin II infusion in
normal rats (group V). In three normal rats on nor-
mal salt intake, angiotensin II infusion at an average
of 200 ng/kg!min increased their blood pressure from
117 6.7 to 146 13.3 mm Hg. While angiotensin II
infusion was maintained unchanged, teprotide was
given. In none of the animals did the converting
enzyme inhibitor produce an effect on mean arterial
pressure (Fig. 4, left panel).
In three salt-depleted rats, angiotensin II at the
same infusion rate produced a slightly smaller
increase in pressure, since it rose from 116 8.0 to
131 2.9mm Hg. Again, this raised arterial pressure
was unaffected by administration of teprotide (Fig. 4,
s right panel).
When the six experiments of group V are com-
bined, mean blood pressure rose during angiotensin
II infusion from 116 5 to 138 7 mm Hg. The
addition of teprotide had no effect on blood pressure,
since it remained unchanged at 138 7 mm Hg.
Teprotide together with angiotensin I and sara-
lasin infusions in normal rats (group VI). In this
series of experiments, angiotensin I was infused con-
tinuously at an average rate of 143 nglkg/min into












Fig. 3. Noraml rats (group Ill, N = 12) and spontaneously
hypertensive rats (SHR) (group IV, N = 6) receiving saralasin
infusion (5 pg/kg/mm) (P113) to which subsequently an iv. bolus
injection of teprotide (1 mg/kg) (SQ) was added. Half of the
animals of each group were maintained on a normal sodium intake,
whereas the others were salt-depleted by dietary restriction. Addi-
tion of teprotide had no effect on blood pressure.
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Fig. 5. Normal rats (group VI, N 8) infused with angiotensin I
(143 or 230 ng/kg/min.) (Al) to which were added subsequently an
infusion of saralasin (5 or 10 ,ug/kg/min) (P113) and an i.v. bolus
injection of teprotide (1 mg/kg) (SQ). Three animals were main-
tained on normal salt intake, and five were salt-depleted by dietary
restriction.
Table 2. Comparison of blocking capacity of teprotide and
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Fig. 4. Normal rats (group V, N = 6) submitted to an angiotensin
II infusion (200 ng/kg/min) (All) to which subsequently an iv.
bolus injection of teprotide (1 mg/kg) (SQ) was added. Again, half
of the animals were sodium-depleted by dietary restriction. Tepro-
tide had no effect on blood pressure.
ma! sodium intake (Fig. 5, left panel). This increased
mean blood pressure from 116 2.1 to 132 to 4.2
mm Hg. When the pressure was stable for at least 15
to 20 mm, a simultaneous infusion of saralasin was
started, which caused the blood pressure to return to
the baseline of 113 3.1 mm Hg. Twenty to thirty
minutes later, with both infusions maintained, injec-
tion of teprotide produced no effect on blood pres-
sure in any of the animals.
In five salt-depleted rats, angiotensin I infusion at
a rate of 230 ng/kglmin also increased blood pressure
by an average of 14 2.7 mm Hg from a basal
pressure of 126 3.3 mm Hg. This higher rate of
angiotensin I infusion was necessary to achieve a rise
in blood pressure similar to that of the rats on normal
salt diet. Accordingly, the rate of saralasin infusion
also was raised to 10 /Lg/kg!min. It caused an imme-
diate descent in pressure to 107 11.8 mm Hg,
followed by recovery to a slightly higher level of 112
8.2 mm Hg. Simultaneous infusions of angiotensin
I and saralasin were continued, and 15 mm later,
teprotide was administered in addition. Blood pres-
sure fell abruptly by an average of 21 5.6 mm Hg
(P <0.02). Within 15 mm, however, it recovered to
the pre-teprotide level of 108 8.8 mm Hg (Fig. 5,
right panel).
When the eight animals of group VI are analyzed
together, blood pressure rose with angiotensin I infu-
sion from 123 3 to 137 3 mm Hg to then settle at
112 5 mm Hg following the addition of saralasin
and immediately prior to adding teprotide. Teprotide
administration had no further sustained effect on
blood pressure, which stabilized at 110 5 mm Hg.
Comparison of angiotensin I inhibition by tepro-
tide and saralasin. Based on the results of groups I
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a Angiotensin I = 32 ng. Complete abolition of the angiotensin
pressor effect following an antagonist was expressed as 100%
inhibition.
on the responses to bolus injections of angiotensin I
(32 ng) were evaluated. Table 2 shows that teprotide
produced 56 4.9% and 81 6.1 % inhibition of the
pressor response to angiotensin I in normal rats on
normal and low-salt diets, whereas saralasin always
caused a 100% inhibition.
Discussion
Previous clinical observations suggested that the
angiotensin I converting enzyme inhibitor, teprotide,
may be more effective than the angiotensin II antago-
nist, saralasin, in blocking angiotensin-induced vaso-
constriction, since only teprotide lowered blood
pressure in patients with normal renin hypertension
[5—71. However, teprotide, even in maximal doses,
blocks converting enzyme only incompletely, and
therefore, one might expect the opposite on theoreti-
cal grounds, namely, that saralasin is more effective
in antagonizing the renin-angiotensin system. On the
other hand, because teprotide simultaneously inhib-
its the main bradykinin inactivating enzyme, kini-
nase II, which has been shown to be identical to
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converting enzyme [3, 41, its hypotensive effect
could be due in part to a vasodilatory action of
bradykinin accumulation. The purpose of our study
was to test whether saralasin is a weaker angiotensin
antagonist than teprotide and, furthermore, to find
out whether some other mechanism such as bradyki-
nm accumulation might be responsible for a differ-
ence in vasodepressor activity of teprotide.
No strict pharmacological comparison was made
since it would have been impossible to also include
dose-response curves of the two inhibitors in the
present experiments. In both rats [12, 13] and
humans [5], dose-response studies have shown that
no further blockade can be obtained by increasing
the dose of teprotide beyond 1 mg/kg. Accordingly,
we chose to use in our experiments this maximally
effective dose. In addition, this is the dose that was
used by those workers who reported a more potent
depressor effect of teprotide [5—7].
In anesthetized normal rats, administration of
teprotide elicited an acute fall of blood pressure. The
pressure decrease in rats on normal diet, however,
was brief. In salt-depleted rats, on the other hand,
blood pressure remained significantly (P < 0.05)
below control levels for as long as one hour after
administration of the antagonist. Thus, only in salt-
depleted animals did teprotide produce sustained
lowering of blood pressure, an effect which has al-
ready been described both in humans [14, 15] and in
animals [16, 17] using either antagonist. That sodium
depletion stimulates renin secretion is well known
[18]. The usual interpretation of the sustained hypo-
tension is that blockade of angiotensin I conversion
removes angiotensin II's contribution to blood pres-
sure maintenance, which appears to be critical after
sodium depletion. It is conceivable that the transi-
tory fall observed even in the rats on normal sodium
diet was related to the anesthesia which is known to
stimulate renin secretion [19—211. Thus, Bing and
Poulsen [21] have observed decreases in blood pres-
sure in anesthetized rats which were absent in con-
scious animals.
To test whether the fall in blood pressure induced
by teprotide was dependent upon angiotensin, we
studied its effects in bilaterally nephrectomized rats
which have no circulating angiotensin [18]. Bilateral
nephrectomy totally abolished both the transitory
and the sustained hypotensive effect of converting
enzyme inhibition, which has also been observed in
anephric patients [7]. Moreover, starting blood pres-
sures were significantly (P < 0.05) lower in the
binephrectomized salt-depleted rats when compared
to the normal salt animals, a finding previously
reported [22]. This latter observation provides sub-
stantial evidence for the removal of a pressor sub-
stance of renal origin, presumably renin. The lack of
a blood pressure effect of teprotide in these animals
with no circulating angiotensin I strongly suggests
that its blood pressure lowering effect is entirely
angiotension-dependent.
There is evidence, however, that the kidney pro-
vides a source of kinins [23, 24] and, thus, nephrec-
tomy may have reduced the circulating bradykinin
[25]. In order to avoid such changes inherent in
nephrectomy, we then attempted to first block the
renin-angiotensin system of normal rats by infusion
of saralasin. As noted by others [8, 9], saralasin
produced an initial rise in blood pressure lasting two
to three minutes. This was immediataly followed in
our experiments by blood pressure changes nearly
identical to those produced by teprotide. More to the
point, however, administration of teprotide in addi-
tion to saralasin produced no further blood pressure
lowering. Thus, again, no evidence for an angioten-
sin-independent blood pressure reduction was pro-
vided by these studies. The magnitude of the fall
induced by saralasin and the absence of a further
pressure-lowering effect by teprotide did suggest that
saralasin was at least as effective in reducing blood
pressure as a maximal dose of the converting enzyme
inhibitor.
Since the vasoconstricted state might provide a
better situation to expose a vasodilator effect of
teprotide, we repeated the above experiments in a
few spontaneously hypertensive rats. Stifi, the addi-
tion of teprotide to saralasin had no detectable effect
on blood pressure, which provides additional indi-
rect evidence against a potential depressor effect due
to bradykinin accumulation. Spontaneoulsy hyper-
tensive rats, however, may have low bradykinin lev-
els, since urinary kallikrein excretion is decreased
[26]. Whatever the case, teprotide was no more
effective than saralasin in reducing blood pressure.
That blood pressure fell to normal levels with
saralasin infusion in the salt-depleted spontaneously
hypertensive rats, however, suggested its angioten-
sin dependence. This observation is surprising in
view of the reported suppression of renin in this
strain [27]. It is compatible, however, with the find-
ing in patients with low-renin essential hypertension
who also responded with a blood pressor fall to
angiotensin II inhibition if sufficiently sodium-deplet-
ed [28].
To induce a vasoconstricted state by a different
means, the blood pressure of normal rats was raised
by angiotensin II infusion. The situation in which
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both angiotensin II levels and peripheral resistance
are increased should have been ideal for demonstrat-
ing a vasodilatory effect of bradykinin accumulation.
But even under these conditions, teprotide failed to
reduce blood pressure in either state of dietary
sodium intake. Thus, if endogenous bradykinin is
capable of exerting a vasodepressor action, it was
not demonstrable in our anesthetized rats. The fail-
ure of teprotide to produce a systemic vasodilatation
due to accumulation of endogenous bradykinin con-
trasts with its potentiation of exogenous bradykinin
[12, 13, 29].
No attempt was made in our studies to measure
bradykinin, but Sancho et al [141 found no elevation
of the plasma concentration in two sodium-depleted
subjects after injection of teprotide. Similarly, in the
dog, Miller et al [30] were unable to demonstrate a
rise of plasma bradykinin after administration of the
converting enzyme inhibitor. On that basis, they had
also concluded that it is unlikely that any hypoten-
sive effect of teprotide was secondary to increased
bradykinin levels, but these studies do not exclude a
bradykinin effect in hypertensive patients [31].
The final set of experiments was designed to com-
pare the potency of the angiotensin-dependent action
of teprotide on blood pressure to that of saralasin. It
was prompted by the notion that there may have
been insufficient angiotensin I present for teprotide
to exert a more potent effect on the renin-angiotensin
system than would saralasin. Accordingly, the "con-
verting enzyme substrate" was increased by infusing
angiotensin I. Even under these conditions, teprotide
had no incremental sustained effect on saralasin-
induced lowering of blood pressure. The transitory
blood pressure drop observed in salt-depleted ani-
mals following teprotide administration is difficult to
account for, but may be related again to anesthesia
[21].
Taken together, these results provide no evidence
that teprotide at a maximally effective dose exerts its
hypotensive effect by any mechanism other than
inhibition of the renin-angiotensin system. Further-
more, in the rat, saralasin appears to be at least as
potent an antagonists of the angiotensin effect as
teprotide. Under certain conditions, however, which
did not pertain in our experiments, the agonistic
effect of saralasin may mask part of its inhibitory
efficacy. Furthermore, we have not excluded the
possibility that part of the blood pressure lowering
effect of either antagonist may be counteracted by
compensatory stimulation of catecholamine secre-
tion. Available evidence [32], however, suggests that
catecholamines are only transiently increased.
Whether these findings made in anesthetized rats can
be extended to conscious man remains to be estab-
lished by further investigations.
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